Pharmacokinetic-Pharmacodynamic Target Attainment Analysis to Support VL-2397 Dose Selection for a Phase 2 Trial in Patients with
Background. VL-2397 is a novel antifungal agent in clinical development for treatment of invasive aspergillosis (IA). The analysis objectives were to: 1) develop a population PK model using data from a Phase 1 trial in healthy adult volunteers, 2) define the PK-PD driver of efficacy in a mouse model of IA, and 3) conduct PK-PD target attainment analyses to aid in Phase 2 dose selection for patients with IA.
Methods. Data from two studies were used: a dose fractionation study in a mouse model of IA and a Phase 1 study in healthy adult volunteers receiving single-and multiple-ascending doses of intravenous (IV) VL-2397 ranging from 3 mg to 1200 mg daily. Mouse lung fungal burden (LFB) measured on Day 4 after infection with Aspergillus fumigatus FP1305 (MIC of 1 µg/mL) was used to assess the predictive value of three measures of VL-2397 exposure: total-drug AUC 0-24 :MIC (tAUC 0-24 :MIC), total-drug C max :MIC, and total-drug %T>MIC; total drug was used because serum protein binding is similar in mice and humans. A population PK model for VL-2397 in humans was developed in NONMEM v7.1.2 and formed the basis of Monte Carlo simulations. The model was also fit to mouse PK data to estimate the VL-2397 exposure in mice.
Results. VL-2397 concentration-time data in humans revealed nonlinear PK behavior consistent with highly-bound compounds. A robust fit to the data was obtained using a two-compartment model with linear elimination and concentration-dependent binding in both central and peripheral compartments. The results of the dose fractionation study suggested that tAUC 0-24 :MIC was the most predictive (r 2 = 0.713) driver of efficacy, with a value of 21.8 on Day 1 associated with a 2-log reduction in LFB on Day 4. Comparisons of the simulated VL-2397 tAUC 0-24 :MIC on Day 1 in humans receiving daily dosing regimens of 300 mg, 600 mg, and 900 mg of VL-2397 to the 2-log target (figure) suggested that a dose of 600 mg Q24 would provide robust (99.9%) PK-PD target attainment up to an A. fumigatus MIC of 2 µg/mL.
Conclusion.
The PK-PD driver of efficacy for VL-2397 was tAUC 0-24 :MIC and a value of 21.8 was associated with a 2-log reduction in LFB in a mouse model of IA. PK-PD target attainment assessments indicate that a VL-2397 dose of 600 mg IV Q24 will provide adequate target attainment up to an MIC of 2 µg/mL. 
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Background.
Clostridium difficile infection (CDI) is the most common cause of diarrhea in hospitals. The only available intravenous (IV) therapy for CDI is metronidazole, which showed only a 52.4% cure rate in a prospective observational study. DS11960558 is a water-soluble prodrug of DS-2969b, which is a novel GyrB inhibitor in clinical development for oral treatment of CDI and has been found to be safe and tolerable in its phase 1 study. The in vivo efficacy and physicochemical, pharmacokinetic, and toxicological profiles of the prodrug were evaluated in this study.
Methods. Efficacy was evaluated in a hamster CDI model. The animals were primed with a single subcutaneous (SC) clindamycin injection. Then, the infection was induced by oral gavage of C. difficile 2009155 (NAP1/027) spores. Treatment was initiated 6 hours post infection and repeated for 5 days. The animals were observed for survival and death once daily for 35 days. The physicochemical, pharmacokinetic, and toxicological profiles were evaluated by standard methods.
Results. SC administration of the prodrug showed comparable and superior efficacy to oral (PO) administration of DS-2969b and the combination of metronidazole (SC) and vancomycin (PO), respectively, in the hamster CDI model (Figure 1 ). The solubility of DS-2969b was 0.4 mg/mL while that of the prodrug was much higher, >100 mg/mL. The prodrug was converted to DS-2969a (free form of DS-2969b) rapidly after IV administration, and the conversion ratio was >80% (Figure 2 ). The main metabolites in rat urine and feces were oxidized forms of DS-2969a, and there were no prodrug-specific metabolites. Fecal excretion of DS-2969a was similar between IV administration of the prodrug and PO administration of DS-2969b. Most of the radioactivity was recovered after IV administration of the 14 C-labeled prodrug in rats. The radioactivity was distributed widely in most tissues including the intestinal lumen, similar to the distribution of DS-2969b in rats. In safety pharmacology, genotoxicity, and rat 14-day repeated dose toxicity studies, the prodrug as well as DS-2969b did not show any significant findings.
Conclusion. These results support development of DS11960558 as an alternative IV treatment option for CDI patients who cannot take medicine orally. Background. ZTI-01 (fosfomycin, FOS, for injection) is currently under US development to treat complicated urinary tract infections. ZTI-01 is unique compared with other antimicrobials in that it inhibits an early step in cell wall synthesis via covalent binding to MurA. ZTI-01 demonstrates broad in vitro activity against Gramnegative (GN) and -positive (GP) bacteria, including multidrug-resistant (MDR) organisms. Our study goals were to determine the efficacy of ZTI-01 as a monotherapy or in combination with meropenem against MDR Pseudomonas aeruginosa in a preclinical model of pulmonary infection.
Disclosures
Methods. 8 week old neutropenic mice were infected with a MDR strain of P. aeruginosa via intubation-mediated intratracheal (IMIT) instillation. 3 hours after instillation, mice received treatment with ZTI-01, meropenem, or ZTI-01 plus meropenem (combination therapy) q8h for 5 days. Mice were monitored every 8 hours for 7 days for development of disease and moribund animals were humanely euthanized. Lungs and spleens were harvested at euthanasia, or at 7 days for survivors, and processed for bacterial enumeration and development of pathology.
Results. Mice were challenged with a lethal dose of P. aeruginosa UNC-D. Mock treated animals succumbed to infection within 36 hours post-infection. Animals that received 6 g/kg/day ZTI-01 showed an increase in the MTD (52 hours) and 25% of the cohort were protected from lethal disease. Combining ZTI-01 with meropenem resulted in a significant increase in survival (≥75% of cohorts survived infection). Combination therapy also significantly decreased bacterial numbers in the lungs and inhibited dissemination to the spleens. Furthermore, animals receiving combination therapy were protected from significant inflammation in the lungs and the development of pneumonia.
Conclusion. Here we report that combination therapy with ZTI-01 and meropenem provides significant improvements in all disease manifestations over treatment with each drug individually in a preclinical model for pulmonary infection with MDR P. aeruginosa. These data strongly support further evaluation of ZTI-01 in combination with other antibiotics as potential therapies against pulmonary infections with MDR bacteria. Friday, October 6, 2017: 12:30 PM Background. The first case of an invasive infection caused by C. auris was reported in July of 2016. Multiple cases have since been reported with high mortality rates due to the multidrug-resistant nature of C. auris. Although C. auris shows increased susceptibility to the echinocandin class of antifungals, the use of these drugs is restricted to multiple IV administrations. CD101 is a novel echinocandin with enhanced stability and pharmacokinetics, allowing for once weekly high dose administration. In this study, we evaluated the efficacy of CD101 in the treatment of disseminated C. auris infection using a murine model of disseminated candidiasis.
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Methods. Female 6-8 week old CD-1 mice were immunosuppressed with cyclophosphamide (200 mg/kg) 3 days prior to infection and 150 mg/kg 1 day post-infection. On the day of infection, mice were inoculated with 3 x 10 7 C. auris blastospores via the lateral tail vein. Mice were randomized into 5 groups (n = 5 for colony forming units (CFU) and n = 10 for survival): CD101 20 mg/kg administered by intraperitoneal (IP) injection, fluconazole 20 mg/kg administered per os (PO), amphotericin B 0.3 mg/ kg IP, and a vehicle control. Treatments were administered 2 hours post-infection (day 1) and again on day 4 of the study for a total of 2 doses. Mice were monitored daily and a survival curve was generated. CFU groups were sacrificed on day 8 of the study. One kidney was removed from each mouse, homogenized, plated on potato dextrose agar (PDA), and incubated at 35°C for 2 days to determine CFU. The remaining survival mice were monitored until the end of the study (day 14).
Results. CD101 showed an average 3 log reduction in kidney CFU compared with fluconazole, amphotericin B, and vehicle treated groups, which was statistically significant (P = 0.03, 0.03, and 0.04, respectively). At the end of the study, percent survival of mice in CD101, fluconazole, amphotericin B, vehicle, and untreated groups was 80, 0, 30, 20, and 0%, respectively (Figure 1) .
Conclusion. Taken together, our findings show that CD101 possesses potent antifungal activity against C. auris infection in a disseminated model of candidiasis. Additionally, treatment with CD101 resulted in a significantly higher overall percent survival. Further investigation of this drug is warranted. 
